세계 전게놈 시퀀싱 시장 규모는 2023년 34억 4,000만 달러에 달했습니다. 이 시장은 2024-2031년 예측 기간 동안 19.31%의 CAGR로 성장하여 2031년에는 141억 2,000만 달러에 달할 것으로 예상됩니다. 의료진이 암, 당뇨병과 같은 만성 및 유전성 질환을 정확하게 진단하고 예측하여 효율적인 치료 계획과 질병 관리 전략을 수립하는 데 도움을 주는 것이 시장 성장의 주요 요인으로 작용하고 있습니다.
전게놈 시퀀싱은 만성질환을 유발하는 유전자 변이를 조기에 발견할 수 있는 수단을 제공합니다. 전게놈 시퀀싱은 낭포성섬유증과 같은 다양한 만성 질환 및 기타 유전자 이상을 정확하게 진단하는 데 사용할 수 있기 때문에 이 산업에 대한 수요가 증가하고 있습니다. 의약품 개발, 농업 연구, 법의학 등 다양한 프로젝트를 수행하는 유전자 연구자들이 증가함에 따라 전게놈 시퀀싱 제품에 대한 수요가 증가하고 있습니다. 이 산업은 과학 연구 개발을 위한 정부 자금과 기술 혁신으로 인해 크게 성장할 것으로 예상됩니다. 그러나 제품 관련 높은 비용, 숙련된 전문가 부족, 복잡한 데이터 해석 등은 전 세계 전게놈 시퀀싱 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
유전자 이상과 만성질환의 발생률 증가는 전게놈 시퀀싱 시장을 크게 견인하고 있습니다. 암, 심혈관 질환 및 기타 질병과 같은 만성 질환의 발생률과 유병률의 증가는 전게놈 시퀀싱에 기반한 진단의 필요성을 촉진하고 있습니다. 많은 질병의 진단과 치료에 전게놈 시퀀싱이 큰 도움을 줄 수 있기 때문에 관련 제품 및 서비스에 대한 수요가 증가하고 있습니다. 전게놈 시퀀싱 기술은 특정 질병 지표를 식별하고 치료에 대한 개인의 반응을 예측할 수 있는 능력으로 인해 점점 더 널리 보급되고 있습니다.
이 보고서는 전 세계 전게놈 시퀀싱 시장을 조사하여 시장 개요와 함께 제품 유형별, 기술별, 생물체별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.
Global whole genome sequencing market size was valued at USD 3.44 billion in 2023 and is expected to reach USD 14.12 billion in 2031, with a CAGR of 19.31% for the forecast period between 2024 and 2031F. The ability of healthcare practitioners to precisely diagnose and predict chronic and genetic diseases, such as cancers and diabetes, which can help in the development of efficient treatment plans and disease management strategies, is acting as a major driver for the market growth.
Whole genome sequencing provides an early means of detecting genetic mutations that cause chronic disease. There is an increasing need for this industry since whole genome sequencing can be used to diagnose various chronic diseases and other genetic abnormalities, such as cystic fibrosis with high precision. Whole genome sequencing products are high in demand due to the growing number of genetic researchers working on various projects such as medication development, agricultural research, and forensics. The industry is anticipated to grow significantly as a result of government funding for scientific research and development as well as technological breakthroughs. However, the high cost associated with products, the lack of highly skilled professionals, and the interpretation of complicated data are some of the hindrances that can hamper the growth of the global whole genome sequencing market.
In March 2023, Illumina Inc. announced the launch of its first product based on its novel Illumina Complete Long Read technology. Illumina Inc. is a global provider of products used in DNA sequencing and array-based technologies. Illumina Complete Long Read Prep, Human is a high-performance, long-read, human whole-genome sequencing (WGS) assay that is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. Illumina Complete Long Reads offers long and short-read sequencing in the same instrument for the first time and enable a simpler workflow as compared to other long-read offerings.
The rising incidence of genetic abnormalities and chronic diseases significantly drives the market for whole genome sequencing. The rising incidence and prevalence of chronic illnesses such as cancer, cardiovascular diseases, and other conditions is fueling the need for whole genome sequencing-based diagnosis. The diagnosis and treatment of many disorders are greatly aided by whole genome sequencing, which has increased demand for related products and services. Whole genome sequencing techniques are becoming increasingly popular due to their ability to identify specific disease indicators and predict individual responses to therapies.
According to a factsheet updated by WHO in September 2023, noncommunicable diseases (NCDs) are responsible for killing 41 million people each year, equivalent to 74% of all deaths globally. Around 17 million people die from NCDs before the age of 70 years; 86% of these premature deaths occur in low- and middle-income countries. Cardiovascular diseases (CVDs) account for most NCD deaths, (17.9 million people annually), followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).
The global whole genome sequencing market is positively impacted by increasing research and development surrounding genome exploration and its various benefits applications. Over the past few decades, the human genome projects have significantly contributed to the growing body of research concerning genome explorations. The market is anticipated to rise significantly in collaboration with the growing acceptance and application of NGS and Sanger technology in institutional and academic research projects.
For instance, in November 2023, UK Biobank Limited released the world's largest-by-far single set of sequencing data by investing EUR 200 million and conducted continuous research for five years into the public domain. The development of innovative diagnostics, therapies, and cures is expected to be fueled by this data. Researchers across the globe can access the data through a secure database that exclusively holds de-identified data.
For precise identification of single nucleotide mutations and minor insertions/deletions, Sanger sequencing is regarded as the gold standard. Sanger sequencing is preferred over other sequencing techniques due to its precision and accuracy. The segment is anticipated to lead the whole genome sequencing market's technology for the duration of the forecasted period due to the growing usage of Sanger sequencing. Numerous industry participants are committed to growing their businesses and offering more fast and accurate whole genome sequencing services.
In October 2023, Wellcome Sanger Institute announced the launch of 'Generative and Synthetic Genomics Program' to enhance research efforts on the 'Human Genetics' and 'Tree of Life' programs. By producing vast volumes of genomic data to feed into computer models will anticipate their consequences, such as the influence of mutations on disease, it seeks to bring together computational and experimental scientists to understand and forecast the impacts of editing DNA. Additionally, the researchers are expected to create tools for writing and editing genomes.
North America is anticipated to dominate the market with the highest value share due to of its significant investment in R&D, technical breakthroughs made by major companies, and highly developed healthcare infrastructure in North American nations like the United States and Canada. Initiatives by the government are expected to expedite medication development process and cancer treatment, contributing to the market growth. In May 2023, The National Institutes of Health (NIH) launched a new program called Common Fund's Somatic Mosaicism Across Human Tissues (SMaHT) Network worth USD 140 million to explore knowledge about genetic variation in normal human cells and tissues.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using various strategies. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their positions in the market.
In July 2023, MedGenome announced the acquisition of Illumina's NovaSeq X Plus. MedGenome is a leading global genomic diagnostic and research services organization in South Asia. The acquisition makes MedGenome the first to offer advanced genomics services using Illumina's NovaSeq X Plus in South Asia. Through the acquisition, the company anticipates cutting down the reagent cost of human whole genome sequencing to USD 200. MedGenome announced the launch of KaryoSeq (or Karyotype Sequencing), which is an innovative whole genome sequencing to diagnose prenatal and newborn conditions.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.